Jane Street Group, LLC Prothena Corp Public LTD CO Call Options Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $192,395 - $285,085	11,500 New	11,500 $192,000
Q1 2022 May 17, 2022	BUY	$30.27 - $49.22 $1.25 Million - $2.04 Million	41,400 Added 140.34%	70,900 $2.59 Million
Q4 2021 Feb 15, 2022	SELL	$42.11 - $73.26 $3.29 Million - $5.72 Million	-78,100 Reduced 72.58%	29,500 $1.46 Million
Q3 2021 Nov 16, 2021	BUY	$48.2 - $78.89 $800,120 - $1.31 Million	16,600 Added 18.24%	107,600 $7.66 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $1.16 Million - $3.09 Million	53,600 Added 143.32%	91,000 $4.68 Million
Q1 2021 May 18, 2021	BUY	$11.0 - $28.24 $327,800 - $841,552	29,800 Added 392.11%	37,400 $939,000
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $212,420 - $342,304	7,600 New	7,600 $279,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $678M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.